Mollugin

Product Specifications

CAS Number

55481-88-4

Target

ROS|||Reactive Oxygen Species|||c-Myc|||NF-?B|||Apoptosis|||VEGFR|||HER|||JAK

Related Pathways

Tyrosine Kinase/Adaptors|||Angiogenesis|||Metabolism|||Immunology/Inflammation|||NF-?B|||JAK/STAT signaling|||Cell Cycle/Checkpoint|||Apoptosis|||Chromatin/Epigenetic|||Stem Cells

Purity

0.9987

Bioactivity

Mollugin (Rubimaillin) may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin as a candidate for a chemotherapeutic agent in OSCCs via the upregulation of the HO-1 and Nrf2 pathways and the downregulation of NF- ? B. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis. Also, it has anticancer efficacy, can modulate the HER2 pathway in HER2-overexpressing Y cells with a potential role in the treatment and prevention of human breast and ovarian Y with HER2 overexpression.